These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 38260271)
1. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. Li X; Liu T; Bacchiocchi A; Li M; Cheng W; Wittkop T; Mendez F; Wang Y; Tang P; Yao Q; Bosenberg MW; Sznol M; Yan Q; Faham M; Weng L; Halaban R; Jin H; Hu Z medRxiv; 2024 Jan; ():. PubMed ID: 38260271 [TBL] [Abstract][Full Text] [Related]
2. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. Li X; Liu T; Bacchiocchi A; Li M; Cheng W; Wittkop T; Mendez FL; Wang Y; Tang P; Yao Q; Bosenberg MW; Sznol M; Yan Q; Faham M; Weng L; Halaban R; Jin H; Hu Z EMBO Mol Med; 2024 Sep; 16(9):2188-2209. PubMed ID: 39164471 [TBL] [Abstract][Full Text] [Related]
3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727 [TBL] [Abstract][Full Text] [Related]
4. MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies. Blewett T; Rhoades J; Liu R; Xiong K; Sridhar S; Crnjac A; Cheng J; Lawless AR; Frederick DT; Flaherty KT; Makrigiorgos GM; Adalsteinsson VA Clin Chem; 2024 Feb; 70(2):434-443. PubMed ID: 38069911 [TBL] [Abstract][Full Text] [Related]
5. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics. Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889 [TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Widman AJ; Shah M; Frydendahl A; Halmos D; Khamnei CC; Øgaard N; Rajagopalan S; Arora A; Deshpande A; Hooper WF; Quentin J; Bass J; Zhang M; Langanay T; Andersen L; Steinsnyder Z; Liao W; Rasmussen MH; Henriksen TV; Jensen SØ; Nors J; Therkildsen C; Sotelo J; Brand R; Schiffman JS; Shah RH; Cheng AP; Maher C; Spain L; Krause K; Frederick DT; den Brok W; Lohrisch C; Shenkier T; Simmons C; Villa D; Mungall AJ; Moore R; Zaikova E; Cerda V; Kong E; Lai D; Malbari MS; Marton M; Manaa D; Winterkorn L; Gelmon K; Callahan MK; Boland G; Potenski C; Wolchok JD; Saxena A; Turajlic S; Imielinski M; Berger MF; Aparicio S; Altorki NK; Postow MA; Robine N; Andersen CL; Landau DA Nat Med; 2024 Jun; 30(6):1655-1666. PubMed ID: 38877116 [TBL] [Abstract][Full Text] [Related]
7. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study. Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379 [TBL] [Abstract][Full Text] [Related]
8. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316 [TBL] [Abstract][Full Text] [Related]
9. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. Chauhan PS; Shiang A; Alahi I; Sundby RT; Feng W; Gungoren B; Nawaf C; Chen K; Babbra RK; Harris PK; Qaium F; Hatscher C; Antiporda A; Brunt L; Mayer LR; Shern JF; Baumann BC; Kim EH; Reimers MA; Smith ZL; Chaudhuri AA NPJ Precis Oncol; 2023 Jan; 7(1):6. PubMed ID: 36658307 [TBL] [Abstract][Full Text] [Related]
10. PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen. Xu J; Pu Y; Lin R; Xiao S; Fu Y; Wang T Front Med (Lausanne); 2022; 9():822200. PubMed ID: 35308511 [TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. Szymanski JJ; Sundby RT; Jones PA; Srihari D; Earland N; Harris PK; Feng W; Qaium F; Lei H; Roberts D; Landeau M; Bell J; Huang Y; Hoffman L; Spencer M; Spraker MB; Ding L; Widemann BC; Shern JF; Hirbe AC; Chaudhuri AA PLoS Med; 2021 Aug; 18(8):e1003734. PubMed ID: 34464388 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Zviran A; Schulman RC; Shah M; Hill STK; Deochand S; Khamnei CC; Maloney D; Patel K; Liao W; Widman AJ; Wong P; Callahan MK; Ha G; Reed S; Rotem D; Frederick D; Sharova T; Miao B; Kim T; Gydush G; Rhoades J; Huang KY; Omans ND; Bolan PO; Lipsky AH; Ang C; Malbari M; Spinelli CF; Kazancioglu S; Runnels AM; Fennessey S; Stolte C; Gaiti F; Inghirami GG; Adalsteinsson V; Houck-Loomis B; Ishii J; Wolchok JD; Boland G; Robine N; Altorki NK; Landau DA Nat Med; 2020 Jul; 26(7):1114-1124. PubMed ID: 32483360 [TBL] [Abstract][Full Text] [Related]
13. Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay. Qi Z; Li Y; Wang Z; Tan X; Zhou Y; Li Z; Zhao W; Zheng X; Yao J; Li F; Wang W; Wang Z; Pang F; Wang G; Gu W Cancer Med; 2023 Aug; 12(16):16687-16696. PubMed ID: 37602656 [TBL] [Abstract][Full Text] [Related]
14. Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study. Arthur C; Rezayee F; Mogensen N; Saft L; Rosenquist R; Nordenskjöld M; Harila-Saari A; Tham E; Barbany G Front Oncol; 2022; 12():899325. PubMed ID: 35865473 [TBL] [Abstract][Full Text] [Related]
15. Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes. Pasca S; Guo MZ; Wang S; Stokvis K; Shedeck A; Pallavajjala A; Shams C; Pallavajjala R; DeZern AE; Varadhan R; Gocke CD; Jones RJ; Gondek LP Blood Adv; 2023 Aug; 7(16):4660-4670. PubMed ID: 37276081 [TBL] [Abstract][Full Text] [Related]
16. Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA. Frydendahl A; Rasmussen MH; Jensen SØ; Henriksen TV; Demuth C; Diekema M; Ditzel HJ; Wen SWC; Pedersen JS; Dyrskjøt L; Andersen CL Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673836 [TBL] [Abstract][Full Text] [Related]
17. Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease. Li Y; Jiang G; Wu W; Yang H; Jin Y; Wu M; Liu W; Yang A; Chervova O; Zhang S; Zheng L; Zhang X; Du F; Kanu N; Wu L; Yang F; Wang J; Chen K EBioMedicine; 2023 May; 91():104553. PubMed ID: 37027928 [TBL] [Abstract][Full Text] [Related]